<DOC>
	<DOCNO>NCT02848248</DOCNO>
	<brief_summary>The study examine safety profile SGN-CD123A . The study test increase dos SGN-CD123A give every 3 week patient .</brief_summary>
	<brief_title>A Safety Study SGN-CD123A Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>This study design evaluate safety , tolerability , preliminary estimate antitumor activity SGN-CD123A . The study conduct 2 part : 1 . Part A dose-escalation portion trial , design identify maximum tolerate dose ( MTD ) SGN-CD123A 2 . Part B dose-expansion portion trial , design evaluate SGN-CD123A patient differ CD123 expression level Dose-escalation Part A conduct use 3+3 study design . Patients CD123-detectable AML enrol cohort escalate dos study drug receive 2 induction cycle SGN-CD123A treatment assign dose level 3-week cycle . After completion dose-escalation , patient enrol Part B study . Patients enrol Part B receive 2 induction cycle SGN-CD123A treatment dose level frequency determine result Part A . For Part A Part B , third induction cycle may permit approval study medical monitor . If patient achieves complete remission complete remission incomplete hematologic recovery , optional post-remission cycle SGN-CD123A may administer .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Relapsed/refractory acute myeloid leukemia follow least 2 3 prior regimen Patients may eligible 1 previous regimen high risk category Adequate baseline renal hepatic function Eastern Cooperative Oncology Group Status 0 1 CD123detectable leukemia Cerebral/meningeal disease relate underlying malignancy Promyelocytic leukemia History clinically significant pulmonary fibrosis document diffuse capacity lung carbon monoxide &lt; 50 % predict Prior hematopoietic stem cell transplant Antileukemia experimental treatment within 4 week study drug ( hydroxyurea 6mercaptopurine ) Cardio cerebral vascular event within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>CD123 Antigen</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>AML</keyword>
	<keyword>Leukemia , Myeloid , Acute</keyword>
</DOC>